Immunotherapies, particularly immune checkpoint inhibitors (ICIs), such as the anti‐PD‐L1, anti‐PD‐1 and anti‐CTLA4, have revolutionized the treatment of cancer.18 This evidence concerns the gene CTLA4 and cancer.